MOUNTAIN VIEW, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for the treatment of glaucoma and retinal diseases, today announced the publication of a landmark peer-reviewed study in Ophthalmology Therapy. This study highlights the sustained safety and efficacy of MicroPulse Transscleral Laser Therapy (TLT) (also referred to as Transscleral Cyclophotocoagulation) in managing both primary and secondary glaucoma over five years. Conducted by Dr. Ronald de Crom and colleagues at the University Eye Clinic Maastricht, Netherlands, this research is the first to evaluate outcomes of MicroPulse TLT over such an extended period.
The study assessed 165 pre- and post-cataract eyes treated between 2016 and 2019, with 112 eyes completing the five-year follow-up. Treatment was delivered using the Iridex Cyclo G6 Laser in its MicroPulse Mode and the original MicroPulse P3 Delivery Device. Results demonstrated that MicroPulse TLT achieved significant (p<0.001) reductions in intraocular pressure (IOP)—32.5% on average—while also enabling a significant reduction (p<0.005) in IOP-lowering medications with a low rate of complications across a broad range of glaucoma types and severities.
"These findings suggest MicroPulse TLT can be a viable alternative to invasive incisional glaucoma surgery, particularly in patients with secondary glaucoma and those for whom incisional surgery may be challenging," said Dr. de Crom. "Its ability to achieve sustained IOP reduction with minimal complications makes it a cornerstone treatment option."
Additionally, over the five-year follow-up period, only 38% of eyes required retreatment. "Patients who underwent retreatments achieved similar levels of success as those treated initially with no significant increase in complication risk." Dr. de Crom continued, "The ability to safely repeat MicroPulse treatments while continuing long-term glaucoma care management without having to progress to more invasive glaucoma surgeries, is a huge advantage to clinicians and patients alike!"
Patrick Mercer, CEO of Iridex, commented, "This is the first long-term, peer-reviewed study that demonstrates the safety, effectiveness, and repeatability of MicroPulse TLT. This milestone study supports our commitment to delivering innovative, non-incisional solutions that improve patient outcomes while creating value for our investors and customers."
About Iridex Corporation
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company's proprietary MicroPulse technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex's current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at .
MicroPulse is a registered trademark of Iridex Corporation, Inc. in the United States, Europe and other jurisdictions. 2024 Iridex Corporation. All rights reserved.
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning clinical expectations and commercial trends, market adoption and expansion, value-maximizing transactions, demand for and utilization of the Company's products and results and expected sales volumes. The Company can provide no assurance that it will complete any value-maximizing transactions on behalf of its stockholders. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2024. Forward-looking statements contained in this announcement are made as of this date and will not be updated.
Media Contact
Joan Staufer
jstauffer@iridex.com
Investor Relations Contact
Philip Taylor
Gilmartin Group
investors@iridex.com
MOUNTAIN VIEW, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for the treatment of glaucoma and retinal diseases, today announced the publication of a landmark peer-reviewed study in Ophthalmology Therapy. This study highlights the sustained safety and efficacy of MicroPulse Transscleral Laser Therapy (TLT) (also referred to as Transscleral Cyclophotocoagulation) in managing both primary and secondary glaucoma over five years. Conducted by Dr. Ronald de Crom and colleagues at the University Eye Clinic Maastricht, Netherlands, this research is the first to evaluate outcomes of MicroPulse TLt over such an extended period.
The study assessed 165 pre- and post-cataract eyes treated between 2016 and 2019, with 112 eyes completing the five-year follow-up. Treatment was delivered using the Iridex Cyclo G6 Laser in its MicroPulse Mode and the original MicroPulse P3 Delivery Device. Results demonstrated that MicroPulse TLt achieved significant (p<0.001) reductions in intraocular pressure (IOP)—32.5% on average—while also enabling a significant reduction (p<0.005) in IOP-lowering medications with a low rate of complications across a broad range of glaucoma types and severities.
"These findings suggest MicroPulse TLt can be a viable alternative to invasive incisional glaucoma surgery, particularly in patients with secondary glaucoma and those for whom incisional surgery may be challenging," said Dr. de Crom. "Its ability to achieve sustained IOP reduction with minimal complications makes it a cornerstone treatment option."
Additionally, over the five-year follow-up period, only 38% of eyes required retreatment. "Patients who underwent retreatments achieved similar levels of success as those treated initially with no significant increase in complication risk." Dr. de Crom continued, "The ability to safely repeat MicroPulse treatments while continuing long-term glaucoma care management without having to progress to more invasive glaucoma surgeries, is a huge advantage to clinicians and patients alike!"
艾裏德克斯的首席執行官帕特里克·默瑟評論道："這是第一項長期的、經過同行評審的研究，展示了MicroPulse TLt的安全性、有效性和重複性。這項里程碑式的研究支持了我們致力於提供創新的無切口解決方案的承諾，這些方案改善了患者的治療效果，同時爲我們的投資者和客戶創造價值。"
關於艾裏德克斯公司
艾裏德克斯公司是全球領先的開發、製造和營銷創新多功能激光醫療系統、輸送裝置及眼科市場耗材設備的公司。公司的專有MicroPulse技術提供了一種差異化的治療方法，爲針對性損害視力的眼部疾病提供安全、有效和可靠的治療。艾裏德克斯目前的產品線用於治療青光眼和糖尿病性黃斑水腫（DME）以及其他視網膜疾病。艾裏德克斯的產品通過直接銷售團隊在美國出售，並通過一網絡獨立分銷商在100多個國家進行國際銷售。如需更多信息，請訪問艾裏德克斯網站。
MicroPulse是艾裏德克斯公司在美國、歐洲及其他司法管轄區的註冊商標。2024 艾裏德克斯公司。保留所有權利。
安全港聲明
本公告包含根據《1933年證券法》第27A條及《1934年證券法》第21E條修正案的前瞻性聲明，包括有關臨床預期和商業趨勢、市場採用與擴展、價值最大化交易、對公司產品的需求和利用以及預期銷售量等聲明。公司無法保證將代表其股東完成任何價值最大化的交易。這些聲明並不是未來業績的保證，實際上可能因多種因素與這些前瞻性聲明中描述的情況有顯著不同。請參閱我們於2024年11月12日向證券交易委員會提交的10-Q季度報告中包含的這些及其他風險的詳細描述。公告中包含的前瞻性聲明的有效期至本日期，並將不再更新。
媒體聯繫
瓊·斯托弗
jstauffer@iridex.com
投資者關係聯繫人
菲利普·泰勒
吉爾馬丁集團
investors@iridex.com
